On January 6, PTC Therapeutics’ chief financial officer divested 2,139 shares, generating proceeds of approximately $164,600. Following this transaction, the CFO’s stake decreased by 2.31%, leaving him with 90,310 shares valued at roughly $6.95 million. The sale was disclosed in an SEC filing, underscoring a broader trend of senior managers reducing positions in recent weeks.

The following day, the chief executive officer sold 3,016 shares for total proceeds near $233,680, trimming his ownership by 0.75%. Post-transaction, the CEO holds 396,967 shares, representing a position valued at over $30.7 million. The sale adds to multiple insider dispositions reported across Form 4 filings, suggesting a phase of portfolio rebalancing at the top executive level.

In its latest quarter, the company delivered earnings per share of $0.20, surpassing consensus estimates by $1.39 and reversing a year-ago loss of $1.39 per share. Revenue rose 7.2% year-over-year to $211.0 million, outpacing the $177.4 million forecast. The business achieved a 42.3% net margin despite a negative return on equity of 194.1%, reflecting significant non-cash charges driving the equity shortfall.

Brokerages remain divided: nine firms maintain buy ratings, seven issue holds and one recommends a sell, resulting in a consensus hold. Jefferies upgraded to buy and lifted its target to 77, while Goldman Sachs retained a sell rating despite raising its target to 50. Barclays moved to equal weight with a 68 objective, Citigroup set a neutral rating at 75, and RBC shifted from outperform to sector perform while boosting its target to 91. These adjustments reflect confidence in recent operational momentum but tempered near-term upside given valuation levels.